In the present study, we focused on a clinical-stage small molecule FAK inhibitor IN10018 (previously known as BI853520 [21, 22]), which has obtained fast-track designation from the U.S. Food and Drug Administration (FDA) and breakthrough designation from China National Medical Products Administration (NMPA) for its combination with PLD in the treatment of platinum-resistant ovarian cancer (PROC) (clinical trial ID: NCT05551507). This evidence concerns the gene PTK2 and ovarian carcinoma.